

June 12, 2019



Lexaria Bioscience Corp. Featured in CannabisNewsWire Publication Describing Dramatic CBD Delivery System Improvements

NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) -- via CannabisNewsWire – [Lexaria Bioscience Corp. \(CSE: LXX\) \(OTCQX: LXR\)](#) today announces its placement in an editorial published by [CannabisNewsWire](#) ("CNW"), a multifaceted financial news and publishing company for private and public entities in the cannabis industry.

To view the full publication, titled "Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments," please visit: <http://cnw.fm/O5Oes>

The popularity of cannabinoid products — those containing active ingredients from cannabis — has created a challenge for producers. While these producers are extracting larger volumes of CBD from cannabis and hemp, much of the precious ingredient goes to waste: the human body only absorbs a small fraction of these molecules because of delivery system limitations and human physiology.

Across the industry, researchers are looking for ways to more effectively deliver CBD into the human body. Thanks to their latest breakthroughs, the scientists at [Lexaria Bioscience Corp. \(CSE: LXX\) \(OTCQX:LXR\)](#) appear to be leading the way.

Results announced in May showed that [LXRs'] DehydraTECH, in combination with generic nanotech techniques, [delivered CBD to the brain 1,137% more efficiently](#) than existing industry formulations. In addition, Lexaria's patented DehydraTECH delivered CBD into the bloodstream in just two minutes and delivered as much CBD in 15 minutes as generic doses did in 60 minutes.

About Lexaria Bioscience Corp.

Lexaria Bioscience has developed and out-licenses its disruptive delivery technology, which promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria's technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins,

nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company's website at www.LexariaBioscience.com.

About CannabisNewsWire (CNW)

CannabisNewsWire ("CNW") is a specialized information service that (1) aggregates cannabis news, (2) provides [CannabisNewsBreaks](#) that quickly updates investors in the space, (3) enhances corporate press releases, (4) helps companies with distribution and optimization of social media, and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of more than 5,000 key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.

For more information please visit <https://www.CannabisNewsWire.com>.

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:
<http://CNW.fm/Disclaimer>.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com



Source: Lexaria Bioscience Corp.